

We claim:

1. A method of treating a patient with cerebral palsy comprising administering a therapeutically effective amount of human allogeneic umbilical cord-derived mesenchymal stromal cells (hCT-MSCs) to the patient.
2. The method of claim 1, wherein the hCT-MSCs are administered systemically.
3. The method of claim 2, wherein the hCT-MSCs are administered intravenously.
4. The method of claim 1, wherein the patient is administered hCT-MSCs three times in a six month period.
5. The method of claim 4, wherein the patient is administered hCT-MSCs at baseline, at three months, and at six months.
6. The method of claim 1, wherein the patient is administered hCT-MSCs at a dose of at least about 2×10^6 /kg.
7. A method of treating a patient with hypoxic- ischemic encephalopathy (HIE) comprising administering a therapeutically effective amount of human allogeneic umbilical cord-derived mesenchymal stromal cells (hCT-MSCs) to the patient.
8. The method of claim 7, wherein the hCT-MSCs are administered systemically.
9. The method of claim 8, wherein the hCT-MSCs are administered intravenously.
10. The method of claim 7, wherein the patient is administered hCT-MSCs three times in a six month period.
11. The method of claim 10, wherein the patient is administered hCT-MSCs at baseline, at three months, and at six months.

12. The method of claim 7, wherein the patient is administered hCT-MSCs at a dose of at least about 2×10^6 /kg.
13. The method of claim 7, wherein the patient with HIE is a newborn 36 weeks gestation or later, who suffers from moderate to severe hypoxic-ischemic neonatal encephalopathy.
14. The method of claim 13, wherein the patient is administered hCT-MSCs in a single dose in the first 48 postnatal hours.
15. The method of claim 14, wherein the patient is administered a second dose of hCT-MSCs approximately two months after the first dose.
16. The method of claim 13, wherein the hCT-MSCs are administered systemically.
17. The method of claim 16, wherein the hCT-MSCs are administered intravenously.
18. The method of claim 13, wherein the patient is administered hCT-MSCs at a dose of at least about 2×10^6 /kg.